The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Mirum Pharmaceuticals Pretax Margin % Related Terms
Mirum Pharmaceuticals Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Mirum Pharmaceuticals's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MIRM vs RYTM, SYRE, PTGX: Pretax Margin % Comparison
For the Biotechnology subindustry, Mirum Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mirum Pharmaceuticals Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Mirum Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirum Pharmaceuticals (MEX:MIRM) has a Pretax Margin % of -493.91% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Mirum Pharmaceuticals and its competitors. According to the industry distribution chart, Mirum Pharmaceuticals ranks #515 out of 939 companies in the Biotechnology industry, placing it in the top 54.8%.
Is Mirum Pharmaceuticals' Pretax Margin % too high?
Mirum Pharmaceuticals' current Pretax Margin % is -493.91%. Based on the distribution chart, Mirum Pharmaceuticals ranks #515 out of 939 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Mirum Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Pretax Margin % compare to RYTM and SYRE?
According to the Biotechnology industry distribution chart, Mirum Pharmaceuticals ranks #515 out of 939 companies for Pretax Margin %. This places Mirum Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Pretax Margin % is -493.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current Pretax Margin % of -493.91%. The stock's GF Value™ is MXN812.06, compared to a current price of MXN1,256.12 — trading 54.7% above its estimated fair value. The current Pretax Margin % is -493.91%. Mirum Pharmaceuticals' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current Pretax Margin % is -493.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?
Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,256.12 is trading 54.7% above its estimated GF Value™ of MXN812.06.
Key valuation signals for MEX:MIRM:
Pretax Margin %: -493.91%
GF Value™: MXN812.06 vs. price of MXN1,256.12 (54.7% above fair value)
No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
46GF Score
Get the complete analysis for MEX:MIRM
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MIRM has been successfully added to your 
